These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31181961)

  • 1. Predictors of isoniazid preventive therapy completion among HIV-infected patients receiving differentiated and non-differentiated HIV care in rural Uganda.
    Tram KH; Mwangwa F; Chamie G; Atukunda M; Owaraganise A; Ayieko J; Jain V; Clark TD; Kwarisiima D; Petersen ML; Kamya MR; Charlebois ED; Havlir DV; Marquez C;
    AIDS Care; 2020 Jan; 32(1):119-127. PubMed ID: 31181961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
    Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D
    AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
    van Griensven J; Choun K; Chim B; Thai S; Lorent N; Lynen L
    Trop Med Int Health; 2015 Dec; 20(12):1823-31. PubMed ID: 26426387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa.
    Jacobson KB; Niccolai L; Mtungwa N; Moll AP; Shenoi SV
    AIDS Care; 2017 Jul; 29(7):936-942. PubMed ID: 28147705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isoniazid preventive therapy completion between July-September 2019: A comparison across HIV differentiated service delivery models in Uganda.
    Mugenyi L; Namuwenge PM; Ouma S; Bakashaba B; Nanfuka M; Zech J; Agaba C; Mijumbi Ojok A; Kaliba F; Bossa Kato J; Opito R; Miya Y; Katureebe C; Hirsch-Moverman Y
    PLoS One; 2024; 19(1):e0296239. PubMed ID: 38166009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of isoniazid preventive therapy completion among adults newly diagnosed with HIV in rural Malawi.
    Little KM; Khundi M; Barnes GL; Ngwira LG; Nkhoma A; Makombe S; Corbett EL; Chaisson RE; Dowdy DW
    Int J Tuberc Lung Dis; 2018 Apr; 22(4):371-377. PubMed ID: 29562983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and predictors of tuberculosis among HIV patients who completed isoniazid preventive therapy (IPT) at Reach out Mbuya community health initiative.
    Sekayi W; Namyalo E; Namayanja J; Kungu JM
    Sci Rep; 2023 Oct; 13(1):17602. PubMed ID: 37845357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiation and completion rates of isoniazid preventive therapy among people living with HIV in Far-Western Region of Nepal: a retrospective cohort study.
    Dhungana GP; Thekkur P; Chinnakali P; Bhatta U; Pandey B; Zhang WH
    BMJ Open; 2019 May; 9(5):e029058. PubMed ID: 31147370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study.
    Sabasaba A; Mwambi H; Somi G; Ramadhani A; Mahande MJ
    BMC Infect Dis; 2019 Jan; 19(1):62. PubMed ID: 30654753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region, Tanzania. A cross-sectional analytical study.
    Robert M; Todd J; Ngowi BJ; Msuya SE; Ramadhani A; Sambu V; Jerry I; Mujuni MR; Mahande MJ; Ngocho JS; Maokola W
    BMC Infect Dis; 2020 Apr; 20(1):276. PubMed ID: 32276618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania.
    Hunter OF; Kyesi F; Ahluwalia AK; Daffé ZN; Munseri P; von Reyn CF; Adams LV
    BMC Infect Dis; 2020 Oct; 20(1):738. PubMed ID: 33028260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of isoniazid preventive therapy among people living with HIV in Kenya: A retrospective study of routine health care data.
    Karanja M; Kingwara L; Owiti P; Kirui E; Ngari F; Kiplimo R; Maina M; Masini E; Onyango E; Ngugi C
    PLoS One; 2020; 15(12):e0234588. PubMed ID: 33264300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis.
    Geremew D; Endalamaw A; Negash M; Eshetie S; Tessema B
    BMC Infect Dis; 2019 May; 19(1):405. PubMed ID: 31077133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study.
    Semu M; Fenta TG; Medhin G; Assefa D
    BMC Infect Dis; 2017 Jan; 17(1):5. PubMed ID: 28049455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoniazid preventive therapy use among patients on antiretroviral therapy: a missed opportunity.
    Kufa T; Chihota VN; Charalambous S; Churchyard GJ
    Int J Tuberc Lung Dis; 2014 Mar; 18(3):312-4. PubMed ID: 24670568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study.
    Kazibwe A; Oryokot B; Mugenyi L; Kagimu D; Oluka AI; Kato D; Ouma S; Tayebwakushaba E; Odoi C; Kakumba K; Opito R; Mafabi CG; Ochwo M; Nkabala R; Tusiimire W; Kateeba Tusiime A; Alinga SB; Miya Y; Etukoit MB; Biraro IA; Kirenga B
    PLoS One; 2022; 17(5):e0266285. PubMed ID: 35576223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi.
    Thindwa D; MacPherson P; Choko AT; Khundi M; Sambakunsi R; Ngwira LG; Kalua T; Webb EL; Corbett EL
    Int J Tuberc Lung Dis; 2018 Mar; 22(3):273-279. PubMed ID: 29471904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
    Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
    Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
    Golub JE; Pronyk P; Mohapi L; Thsabangu N; Moshabela M; Struthers H; Gray GE; McIntyre JA; Chaisson RE; Martinson NA
    AIDS; 2009 Mar; 23(5):631-6. PubMed ID: 19525621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Isoniazid Preventive Therapy Care Cascade Among HIV-Positive Female Sex Workers in Mombasa, Kenya.
    LaCourse SM; Deya RW; Graham SM; Masese LN; Jaoko W; Mandaliya KN; Overbaugh J; McClelland RS
    J Acquir Immune Defic Syndr; 2017 Sep; 76(1):74-81. PubMed ID: 28797022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.